Drug Trial Radar · NCT06468462
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,900
Planned (sponsor's estimate)
Start
Oct 29, 2025
Primary completion
Oct 31, 2028
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aurum Institute; Nyanza Reproductive Health Society; National Institute of Allergy and Infectious Diseases (NIAID); Partners for Health & Development in Africa
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 29 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Men who have sex with men (MSM) are at high risk for gonorrhea and chlamydia in Kenya, where nucleic acid amplification testing is not feasible and most infections therefore go undiagnosed. We propose an open-label randomized clinical trial with 2900 participants assigned to WHO-recommended periodic presumptive treatment (PPT) or doxycycline post-exposure prophylaxis (doxyPEP), compared to standard syndromic treatment, with 18 months of follow-up and rigorous culture-based and molecular analysis of antimicrobial resistance in Neisseria gonorrhoeae. This work will provide critical data needed to inform guidelines and improve STI control among MSM in sub-Saharan Africa and other resource-limited settings, including modelled estimates of the health and economic impact of scaling up these two interventions on STI control among MSM and their partners in Kenya.
Conditions
- Gonorrhea Male
- Chlamydia (Male)
- Syphilis Male
Interventions
WHO-recommended periodic presumptive treatmentDrug
400 mg po cefixime plus 1 gram azithromycin po under direct observation
Doxycycline post-exposure prophylaxisDrug
200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with NG, CT, or early syphilis infection (combined STI outcome)Time frame: Over 18 months of follow-up at quarterly visits from the date of randomization
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Anza Mapema Clinic
Kisumu, Kenya
University of Washington/Pwani Research Centre at the Ganjoni Municipal Clinic, Mombasa
Mombasa, Kenya
TRANSFORM Clinic
Nairobi, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.